CDER Director Sees Behind-The-Counter Switches As Best Bet
This article was originally published in The Pink Sheet Daily
Woodcock's comments at the recent Food and Drug Law Institute conference in Washington indicate the idea is far from dead at the agency.
You may also be interested in...
FDA drug center chief Janet Woodcock says behind-the-counter switches would be the most effective method to make Rx drugs available without prescriptions, particularly to help treat chronic conditions.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.